Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism
- Disease/Condition
- Osteoporosis
- Drug/Device/Intervention
- Stage 1
- Study type
- Interventional
- Intervention type
- dietary supplement
- Primary sponsor
- National Yang Ming University
- Location
- Taipei,Taipei, Taiwan
- Phase
- N/A
- Start date
- Apr 08, 2024
- End date
- Dec 01, 2024
- Enrollment
- 20 participants
General examination,Hematology Test
Compared with traditional calcium supplements, liposome calcium can increase the
 bioavailability of calcium and reduce the waste caused by gastric acid destruction of
 calcium. This allows calcium to be released slowly in the intestines, reducing the risk of
 indigestion or other side effects caused by excessive intake at one time. Liposomal calcium
 can be taken orally directly. It does not need to be dissolved in water before taking like
 other calcium supplements, making it more convenient to use. Based on the above advantages,
 liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for
 long-term use, and can meet the body's demand for calcium. According to the recommendations
 of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg.
 In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for
 Chinese people recommends that the daily intake for adults should be 1,000 mg. The calcium
 dose used in this study was 500 mg. The purpose was to explore whether the sustained-release
 characteristics of liposome coating technology can improve the absorption rate after
 consuming calcium powder and achieve better bioavailability. It is expected that microlipids
 made by lecithin can Lipid calcium powder increases its maintenance time in the blood,
 thereby increasing the supplementary effect of calcium, and is an alternative to calcium
 supplements.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06372158
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06372158 through Pure Global AI's free database. This phase not specified trial is sponsored by National Yang Ming University and is currently Recruiting. The study focuses on Osteoporosis. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.